XML 66 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Details)
 3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | segment 1  
Segment Reporting Information [Line Items]    
Revenue from collaborative arrangements $ 65,343 $ 0
Less:    
Research and development expenses 16,090,902 20,913,790
General and administrative 9,024,970 10,571,179
Total operating expenses 25,115,872 31,484,969
Interest income 808,077 1,500,290
Interest expense 0 (177,833)
Change in fair value of common stock warrant liability 3,712,872 0
Gain (loss) on investment in affiliated entity 695,131 (126,018)
Net unrealized gain on available-for-sale equity securities 140,234 500,877
Other expense, net (482) (682,218)
Net loss (19,694,697) (30,469,871)
INO-3107    
Less:    
Research and development expenses 3,507,342 7,645,664
INO-3112 And Other Immuno-oncology    
Less:    
Research and development expenses 1,315,084 2,020,750
Other programs    
Less:    
Research and development expenses 107,425 623,666
Engineering and device-related    
Less:    
Research and development expenses 5,061,810 3,751,261
Stock-based compensation    
Less:    
Research and development expenses 553,394 1,060,487
Other unallocated expenses    
Less:    
Research and development expenses 5,545,847 5,811,962
Reportable Segments    
Segment Reporting Information [Line Items]    
Revenue from collaborative arrangements 65,343 0
Less:    
General and administrative 9,024,970 10,571,179
Total operating expenses 25,115,872 31,484,969
Interest income 808,077 1,500,290
Interest expense 0 (177,833)
Change in fair value of common stock warrant liability (3,712,872) 0
Gain (loss) on investment in affiliated entity 695,131 (126,018)
Net unrealized gain on available-for-sale equity securities 140,234 500,877
Other expense, net (482) (682,218)
Net loss $ (19,694,697) $ (30,469,871)